Cart
sales@molnova.com
SKLB 610
CAS No. 1125780-41-7
SKLB 610( SKLB610 | SKLB 610 | SKLB-610 )
Catalog No. M10442 CAS No. 1125780-41-7
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 62 | In Stock |
|
| 5MG | 36 | In Stock |
|
| 10MG | 70 | In Stock |
|
| 25MG | 116 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSKLB 610
-
NoteResearch use only, not for human use.
-
Brief DescriptionSKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR.
-
DescriptionSKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.
-
In Vitro——
-
In Vivo——
-
SynonymsSKLB610 | SKLB 610 | SKLB-610
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR| PDGFR| VEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1125780-41-7
-
Formula Weight415.37
-
Molecular FormulaC21H16F3N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(NC)C1=NC=CC(OC2=CC=C(NC(C3=CC=CC(C(F)(F)F)=C3)=O)C=C2)=C1
-
Chemical NameN-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Shah A, Mangaonkar A. Ann PharmacOthers. 2015 Jul 16.
molnova catalog
related products
-
LY2874455
LY2874455 is a potent, selective pan-FGFR inhibitor.
-
Amlexanox
Amlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.
-
Pemigatinib (INCB054...
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.
